Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Rezolve AI has entered a new phase of borrow stress, with availability collapsing from 22% to near-zero in a single session even as the stock fell 15% on the week.
The lending market tells the most urgent story right now. Availability dropped to just 0.12% on October 13, down from 22.3% the day before. That is effectively zero: for every 800 shares already lent out, fewer than one remains available to borrow. The 52-week low on availability is 0.07%, so the pool is close to its tightest point on record. Cost to borrow has followed the same path, climbing to 42.3% from 18.7% a month ago and more than doubling on the week. That is before accounting for the October 8 spike to 60%, which briefly pushed borrowing costs to levels last seen only in the September squeeze episode. Short interest itself has continued grinding higher: 14.6% of free float, up 4.5% on the week and nearly 10% over the past month. The ORTEX short score stands at 80.0, placing RZLV in the top 1% of the universe for bearish positioning. Bears who absorbed the September squeeze, held through the earnings print on October 6, and kept adding through the week's 15% decline are now paying premium rates for increasingly scarce borrows.
Options positioning reinforces the bearish lean. The put/call ratio is at 0.31, more than two standard deviations above its 20-day average of 0.26, and near the 52-week high of 0.33. That is the highest concentration of put buying relative to call buying seen in a year. Investors are paying for downside protection on a stock that is already down 20% on the month, suggesting the options market sees more risk to the downside rather than a near-term reversal.
The ownership register adds a complicating layer. CEO Daniel Wagner filed a Schedule 13D/A on August 28, the most recent of four filings since March 2025. He is a confirmed activist on the register under ORTEX's EDGAR data. His latest disclosed stake was 13.8% of the class, down from 15.6% in the prior filing. Wagner made open-market purchases totalling roughly $3.25 million in early April at $4.00 per share, which means he is sitting on a loss of more than half on that tranche at the current $1.83 price. No further open-market buying appears in the insider record since then. Alejandro Gonzalez filed a 13G/A in July disclosing 7.5% of the class, up from 5.7%, with 7.25 million shares added per the most recent institutional report. So while the CEO's stake has dipped, at least one other large holder has been building. As with all 13D/G disclosures, these stakes reflect positions as last filed, and holders dropping below 5% may not file again. The disclosure caveat applies.
Among correlated peers, CYN fell 21% on the week while REKR and CRNC gained 10%. The divergence suggests the pressure on RZLV is at least partly stock-specific rather than a sector-wide de-rating. The December 2 earnings date is the next hard catalyst on the calendar. Between now and then, the key variable is whether the borrow pool remains at or near exhaustion: if shorts cannot add at current rates, the pressure on availability and cost to borrow will determine how the positioning picture evolves into year-end.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
